The Biospecimen and Pathology Core ofthe Breast SPORE is responsible for accessioning and processing new biospecimens for the Breast SPORE Biospecimen Repository and to make those specimens available for use in the four SPORE main projects and very likely for the Developmental Research and Career Development Programs. Biospecimens will also be made available to other intra- and extra-mural investigators engaged in breast cancer translational research. Requests for biospecimens will be taken under consideration by the Breast SPORE Operations Committee, with a heavy emphasis on scientific merit and on availability of specimens and their associated data needed for analysis. Input from the Biostatistics and Patient Registry Core is included in the evaluation of requests for tissues. The Pathology Team of the Biospecimen Core will provide detailed annotations in the Breast Pathology Database for frozen and formalin-fixed paraffin-embedded tissues from selected cohorts of patients to support SPORE projects and additional projects for which the Breast Biospecimen Repository has provided tissues. The Core pathology team will also interpret IHC staining. The Biospecimen and Pathology Core will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing Shared Resource to process blood samples to provide genomic DNA and serum aliquots, and with the Tissue and Cell Molecular Analysis Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray construction, and digital imaging. Working closely with existing infrastructure such as these shared resources minimizes redundancy of services and utilizes existing experience and state ofthe art equipment. New immunostaining assays will be developed by the Biospecimen and Pathology Core, as well as construction of cell line tissue microarrays to screen and test antibodies for immunostaining formalin-fixed, paraffin-embedded tissues.

Public Health Relevance

The Biospecimen and Pathology Core provides the biospecimens (frozen tissue, FFPE tissue, tissue microarrays and cell line microarrays, blood, serum, DNA, and RNA), pathology annotations, histological services, and pathology support necessary to support the projects of the Mayo Clinic Breast Cancer SPORE as well as other breast cancer translational research projects. The Core also provides histology-related services, such as sectioning, immunostaining, antibody optimization and characterization, and digital imaging. Core pathologists provide IHC interpretations. These functions are essential to most translational research, including the specific projects included in this SPORE proposal.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
(2015) Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 24:285-98
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Ingle, James N; Kalari, Krishna R; Buzdar, Aman U et al. (2015) Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids 99:32-8
Kiiski, Johanna I; Pelttari, Liisa M; Khan, Sofia et al. (2014) Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A 111:15172-7
Whiley, Phillip J; Parsons, Michael T; Leary, Jennifer et al. (2014) Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation. PLoS One 9:e86836
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
D'Assoro, A B; Liu, T; Quatraro, C et al. (2014) The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER*(+) breast cancer cells. Oncogene 33:599-610
Agarwal, D; Pineda, S; Michailidou, K et al. (2014) FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer 110:1088-100
Abdel-Aal, Abu-Baker M; Lakshminarayanan, Vani; Thompson, Pamela et al. (2014) Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem 15:1508-13
Joshi, Poorval M; Sutor, Shari L; Huntoon, Catherine J et al. (2014) Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 289:9247-53

Showing the most recent 10 out of 202 publications